Implantation of iodine125-Seeds Combined With Chemotherapy in the Treatment of Metastatic Pancreatic Carcinoma

Inclusion Criteria: (Before the trial, subjects must meet all of the requirements listed below in order to be enrolled) 18 to 80 years old; Stage IV pancreatic ductal adenocarcinoma with distant metastases confirmed by clinical, imaging, and pathology, and the primary and metastatic mass can be measured on imaging. No treatment history of chemotherapy, radiotherapy, or surgery Expected survival > 6 months ECGO score of 0-2 Eligible for chemotherapy (white blood cell > 3.5×109/L, neutrophil value > 1.5×109/L, hemoglobin > 80g/L, platelets > 100×109/L, albumin > 25g/L, alanine aminotransferase or aspartate aminotransferase ≤ 3 times the upper limit of normal and total bilirubin level ≤ 34.2umol/L, creatinine < 176.8 umol/L, normal ECG) Signed written informed consent; Exclusion Criteria: Contraindication of EUS-guide procedure or technical infeasibility (e.g.,coagulation disorder, anatomical changes, large vessels along the puncture path) Pregnant or breastfeeding Presence of brain metastases Presence of deep vein thrombosis or pulmonary embolism Presence of HIV, HBV, HCV infection or other uncontrollable active infection Hypersensitivity to chemotherapy drugs History of other malignancies within 5 years Peripheral neuropathy or interstitial lung disease within 5 years Patient is enrolled in any other clinical protocol or investigational trial.